转移性激素初治前列腺癌 (mHNPC) 通常是转移性前列腺癌的最初表现形式，涵盖异质性患者群体，患者之间的预后和治疗反应具有高度异质性。在循证生物标志物的指导下，对 mHNPC 进行更精确的治疗仍然是一个未得到满足的医疗需求。此外，mHNPC代表性实验室模型数量有限，阻碍了基础研究向临床应用的转化。我们全面概述了 mHNPC 的临床和生物学特征，重点介绍了可以解释 mHNPC 独特预后特征的分子数据，并确定了关键的开放性问题。版权所有 © 2024 作者。由爱思唯尔公司出版。保留所有权利。

Metastatic hormone-naïve prostate cancer (mHNPC) is often the initial form of presentation for metastatic prostate cancer and encompasses a heterogeneous patient population with high inter-patient heterogeneity in prognosis and response to therapy. A more precise treatment of mHNPC, guided by evidence-based biomarkers, remains an unmet medical need. In addition, the limited number of representative laboratory models of mHNPC hampers the translation of basic research into clinical applications. We provide a comprehensive overview of the clinical and biological features that characterize mHNPC, highlight molecular data that could explain the unique prognostic characteristics of mHNPC, and identify key open questions.Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.